SEC Comment Letter 0000000000-24-007969 to Hepion Pharmaceuticals, Inc. (HEPA)
Hepion Pharmaceuticals, Inc.
Date: July 12, 2024 · CIK: 0001583771 · Accession: 0000000000-24-007969
AI Filing Summary & Sentiment
File numbers found in text: 333-280752
Letter
July 12, 2024 John Cavan Interim Chief Executive Officer Hepion Pharmaceuticals, Inc. 399 Thornall Street, First Floor Edison, NJ 08837 Re:Hepion Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed July 11, 2024 File No. 333-280752 Dear John Cavan: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Sean Reid
Show Raw Text
July 12, 2024
John Cavan
Interim Chief Executive Officer
Hepion Pharmaceuticals, Inc.
399 Thornall Street, First Floor
Edison, NJ 08837
Re:Hepion Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed July 11, 2024
File No. 333-280752
Dear John Cavan:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Sean Reid